An interventional study of Culturally adapted cervical cancer screening invitation letter and Standard cervical cancer screening invitation letter in Cervical Cancer Screening, Cervical Cancer and Cervical Cancer (Early Detection), sponsored by The Primary Health Care in the Capital Area. Not yet recruiting at 1 site in Iceland. Open to female participants aged 23 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by The Primary Health Care in the Capital Area · Not applicable, Interventional, and Health services research
This study tests whether sending Polish women residing in Iceland a culturally adapted invitation letter - tailored in language and messaging to the target group - increases participation in cervical cancer screening compared with a standard, non-adapted invitation letter. Eligible women will be randomly assigned to receive one of the two letter types, and screening participation will be tracked over the following months.
It has been shown that cervical cancer screening participation remains lower among women with immigrant background, compared to the general population. Translating existing screening materials into the languages of the immigrant groups may not be sufficient to motivate screening participation. However, cultural adaptation of cancer screening materials has been suggested as a potential strategy to facilitate screening attendance.
This study investigates whether a culturally adapted invitation letter increases attendance at cervical cancer screening among Polish women residing in Iceland, compared with the standard invitation letter currently used in the national cervical cancer screening program. The adapted letter was developed in collaboration with a focus group from the target population.
All individuals registered as female in Registers Iceland and aged 23-64 years are eligible for cervical cancer screening in accordance with the national cancer screening guidelines issued by the Directorate of Health. Eligible individuals receive an invitation letter both digitally via the national health portal and by post. All eligible individuals receive digital invitations in Icelandic, English and Polish. Paper invitations are available only in Icelandic. Therefore, the culturally adapted letter will only be sent digitally.
Polish-born women residing in Iceland who are due for routine cervical cancer screening will be randomized 1:1 to receive either the culturally adapted invitation letter or the standard invitation letter.
This trial is intended to generate evidence on whether low-cost intervention, such as the cultural adaptation of existing screening materials, may help reduce disparities in screening uptake.
1,881 studies on the registry are indexed under Uterine Cervical Neoplasms; 567 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 100 across 1,377 interventional studies indexed under Uterine Cervical Neoplasms.
Browse Uterine Cervical Neoplasms studies →This is the only study on the registry with The Primary Health Care in the Capital Area as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
-Individuals who are not eligible for the national cervical cancer screening program in Iceland (non-female, outside the screening age and not due for an invitation (time since last screening attendance)).
Participants in this arm receive a screening invitation letter which has been culturally adapted, developed with community input.
Behavioral: Culturally adapted cervical cancer screening invitation letter
Participants in this arm receive a standard invitation letter to cervical cancer screening.
Behavioral: Standard cervical cancer screening invitation letter
Participants randomized to the intervention group will receive a screening invitation letter which has been culturally adapted, developed with community input from individuals in the target group. The letter provides information about cervical cancer screening and has been adapted to the language, cultural context, and communication needs of the target population of Polish women residing in Iceland. The adapted letter retains the essential information contained in the standard invitation while modifying its wording and presentation to improve relevance, understanding, and engagement, with the aim of increasing attendance at cervical cancer screening. The letter will be sent once digitally via the electronic health platforms heilsuvera.is and island.is.
Participants randomized to the control group will receive the standard invitation letter routinely used to invite eligible individuals to cervical cancer screening. The standard letter provides information about the screening programme and instructions for attending screening. The letter will be sent once digitally via the electronic health platforms heilsuvera.is and island.is.
Participation rate in the national cervical cancer screening program in Iceland
The primary outcome of this study will be the participation rate in the Icelandic national cervical cancer screening program within 6 months of invitation, defined as a registered cervical sample in the Icelandic Cancer Screening Register. Participation will be coded as a binary variable (yes/no).
Time frame: From the date the invitation is sent through 6 months post-invitation.
Participation rate in the national cervical cancer screening program in Iceland
The secondary outcome will be the participation rate in the Icelandic national cervical cancer screening program within 3 months of invitation, defined as a registered cervical sample in the Icelandic Cancer Screening Register. Participation will be coded as a binary variable (yes/no).
Time frame: From the date the invitation is sent through 3 months post-invitation.
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.